TABLE 4.
Reciprocal UBTs for linezolid and ciprofloxacin in the 12 volunteers testeda
| Drug and strainb | UBT for the following collection period (h):
|
AUBT (h−1) | |||||||
|---|---|---|---|---|---|---|---|---|---|
| 0-6 | 6-12 | 12-24 | 24-36 | 36-48 | 48-72 | 72-96 | 96-120 | ||
| Linezolid | |||||||||
| S. aureus ATCC 27278 | 128c (16-≥1,024) | 48 (16-512) | 16 (4-256) | 4 (1-32) | 1.5 (0-8) | 0 (0-4) | 0 (0-2) | 0 (0-2) | 180 (144-390) |
| S. aureus 636 (MS, CR) | 256c (64-≥1,024) | 96c (15-512) | 64c (8-256) | 8c (0-32) | 1.5c (0-4) | 0c (0-1) | 0 | 0 (0-1) | 252c (120-444) |
| S. aureus U6991 (MR, CR) | 256c (32-≥1,024) | 64c (16-512) | 32c (8-256) | 6c (0-32) | 2c (0-16) | 0 (0-4) | 0 | 0 (0-1) | 237c (138-408) |
| S. saprophyticus Ho 94 (MS) | 128c (32-512) | 64 (32-128) | 32 (16-128) | 4 (1-64) | 2 (0-16) | 0 (0-4) | 0 (0-1) | 0 | 210 (156-420) |
| E. faecalis 60 | 96c (2-256) | 32c (1-128) | 24c (0-64) | 2c (0-32) | 1c (0-8) | 0 (0-4) | 0 | 0 | 141 (18-378) |
| E. faecium 106 | 96 (2-512) | 32c (1-64) | 16c (0-64) | 2 (0-32) | 1c (0-8) | 0 (0-2) | 0 (0-1) | 0 | 168c (18-372) |
| Ciprofloxacin | |||||||||
| S. aureus ATCC 27278 | 512c (8-≥1,024) | 64 (16-128) | 32 (2-128) | 4 (2-8) | 1 (0-4) | 0 (0-2) | 0 | 0 | 228 (138-282) |
| S. aureus 636 (MS, CR) | 1.5c (0-16) | 0c (0-2) | 0c (0-2) | 0c | 0c | 0c | 0 | 0 | 18c (0-60) |
| S. aureus U6991 (MR, CR) | 1.5c (0-32) | 0c (0-4) | 0c (0-2) | 0c (0-1) | 0c | 0 (0-1) | 0 | 0 (0-1) | 12c (0-66) |
| S. saprophyticus Ho94 (MS) | 384c (16-≥1,024) | 64 (32-256) | 32 (8-128) | 4 (2-8) | 2 (1-4) | 0 (0-2) | 0 | 0 (0-1) | 234 (150-264) |
| E. faecalis 60 | 64c (0-≥1,024) | 16c (4-32) | 4c (0-32) | 0c (0-1) | 0c | 0 | 0 | 0 | 108 (66-174) |
| E. faecium 106 | 64 (2-256) | 16c (4-32) | 4c (2-16) | 0.5 (0-2) | 0c (0-1) | 0 | 0 | 0 | 114c (66-130) |
a
The values are medians (ranges).
b
MS, methicillin sensitive; MR, methicillin resistant; CR, ciprofloxacin resistant.
c
Significantly different (P < 0.05, paired t test) for linezolid versus ciprofloxacin.